Table 3.
Meta-analysis results of Profile comparison for STN DBS vs. GPi DBS.
| Item | I2statistic | Mean and 95%CI (fixed-effect model) | Mean and 95% CI (randomized-effect model) |
|---|---|---|---|
| Age | 31% | 1.34 [0.12, 2.56] | 1.78 [0.09, 3.47] |
| Duration of disease (month) | 87% | −0.16 [−0.57, 0.89] | −0.06 [−2.30, 2.17] |
| LED (mg/day) | 39% | −17.34 [−97.39, 62.71] | −2.56 [−109.97, 104.84] |
| UPDRS off-med | 0% | 1.58 [−0.34, 3.49] | 1.58 [−0.34, 3.49] |
| UPDRS on-med | 0% | 0.40 [−1.11, 1.90] | 0.40 [−1.11, 1.90] |
| dyskinesia | 46% | −0.10 [−0.24, 0.04] | −0.11 [−0.33, 0.11] |
CI, confidence interval; GPi, globus pallidus interna; LED, Levodopa equivalent doses; STN, subthalamic; UPDRS, unified Parkinson's disease rating score.